IDEXX Q4 revenue $801M (+11%), full-year EPS $8.60 (+28%); guides 2022 revenue $3.5-$3.565B

IDEXX LABORATORIES INC /DE

2021-FY EPS reported $8.60 revenue$3,215,360,000

Q4 revenue $801M, up 11% reported and 10.5% organic; CAG Diagnostics recurring revenue grew 13%.
Full-year EPS $8.60, up 28% reported and 29% comparable; operating margin expanded 330 bps reported.
Record premium instrument placements drove 14% YoY expansion of global installed base.
Initial 2022 guidance: revenue $3,500M-$3,565M (9-11% growth), EPS $9.27-$9.59 (8-11% growth).
U.S. same-store clinical visit growth 2% in Q4; on a two-year basis, visits up 5.5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.